Health Care

More

• Talking Numbers: Buy Humana or United Healthcare?  Tuesday, 2 Apr 2013 | 3:30 PM ET

  

  Which health insurance stock can keep your portfolio strong? Enis Taner, RiskReversal.com and Zachary Karabell, River Twice Research, discuss.

• HMOs Pop on Medicare Decision  Tuesday, 2 Apr 2013 | 2:10 PM ET

  

  HMO stocks jumped on decisions on 2013 Medicare rates, but is this all roses? CNBC's Scott Cohn and Ipsita Smolinski, offer insight.

• HMOs: A Reversal of Fortune  Tuesday, 2 Apr 2013 | 1:42 PM ET

  

  HMO stocks jumped on decisions on 2013 Medicare rates, with CNBC's Scott Cohn.

• UPDATE 1-Optimer shares rise after report names Glaxo, Cubist as potential buyers Tuesday, 2 Apr 2013 | 2:29 PM ET

  *Optimer could get $15- $16/ shr- analyst. April 2- Shares of Optimer Pharmaceuticals Inc rose as much as 24 percent after a Bloomberg report said GlaxoSmithKline Plc and Cubist Pharmaceuticals Inc were among those interested in buying the antibiotic maker. The report also named AstraZeneca PLC and Japan's Astellas Pharma Inc as potential buyers.

• Vanguard Health rebounds on Medicaid contract Tuesday, 2 Apr 2013 | 2:28 PM ET

  NASHVILLE, Tenn.-- Shares of hospital operator Vanguard Health Systems took back some ground Wednesday after the company said it had secured a three-year contract to manage Medicaid patients in Arizona. It had said last month that Arizona wasn't renewing a bigger Medicaid contract.

• New-look Sarepta eyes approval for muscular dystrophy drug Tuesday, 2 Apr 2013 | 1:51 PM ET

  *Under new CEO, Sarepta focused on Duchenne muscular dystrophy drug. *Analysts expect company to relay FDA feedback in April. April 2- After three decades without bringing a drug to market, Sarepta Therapeutics Inc stands on the verge of a breakthrough with its treatment for a crippling genetic disorder that affects one in every 3,500 newborn boys.

• HMOs Jump on 2013 Medicare Rates  Tuesday, 2 Apr 2013 | 12:41 PM ET

  

  Health insurance stocks like Humana broke out sharply on Monday after the CMS increased the Medicare Advantage rate. The FMHR traders and Steve Grasso discuss how to play these stocks. Also, whether to get cautious on news the Dow has set a new intraday high in 12 of the past 20 trading sessions, with Jason Pride, Glenmede.

• UPDATE 2-Obagi Medical gets higher offer from Merz Pharma Tuesday, 2 Apr 2013 | 12:44 AM ET

  April 2- Neurological and dermatology drugs maker Merz Pharma Group offered to buy cosmetic products maker Obagi Medical Products Inc for $383.5 million, topping a bid by Canada's Valeant Pharmaceuticals International Inc. Merz's $22- per-share bid represents a premium of 11 percent to Valeant's offer of $19.75.

• HMO Stocks on a Surge  Tuesday, 2 Apr 2013 | 11:32 AM ET

  

  CNBC's Bertha Coombs explains how a change in budget calculations sent some health insurance shares higher.

• Health Insurers Soar on Medicare Rate Rise  Tuesday, 2 Apr 2013 | 10:32 AM ET

  

  CNBC's Bertha Coombs explains why the government's new program for Medicare and Medicaid has sent some insurers soaring.

• ANALYSIS-Big Pharma down, not out, after Indian patent blow Tuesday, 2 Apr 2013 | 10:48 AM ET

  LONDON/ MUMBAI, April 2- Stung by a landmark patent defeat, Western drugmakers will be wary about launching new products in India, but they cannot afford to quit a country tipped to be the world's eighth largest market for medicines by 2016..

• 6th Annual World Autism Awareness Day  Tuesday, 2 Apr 2013 | 9:40 AM ET

  

  Bob and Suzanne Wright, co-founders of Autism Speaks, discuss the organization's efforts to foster research and raise awareness about Autism.

• Booster Shot For Health Insurers  Tuesday, 2 Apr 2013 | 7:42 AM ET

  

  Sarah James, Wedbush Securities analyst, reveals her outlook on health care companies, after a recent report indicates an estimated growth rate of 3.3% for insurers.

• CMS Assumes No Change for 2014  Monday, 1 Apr 2013 | 4:55 PM ET

  

  Health insurance stocks are moving higher on the decision from the Center for Medicare Services--CMS says they will not propose a cut to Medicare reimbursement rates, reports CNBC's Bertha Coombs.

• Johnson & Johnson Hits All-Time High  Monday, 1 Apr 2013 | 2:38 PM ET

  

  Johnson & Johnson just won approval for a new diabetes drug, and the stock is at an all-time high today. Anthony Butler, Barclays, offers insight.

• Health Care & Your Retirement  Monday, 1 Apr 2013 | 1:45 PM ET

  

  Enrollment season for Medicare Advantage plans and Obama's health reform plan is six months away. One big question is how many people will show up to be insured, reports CNBC's Bertha Coombs.

• Ready or Not: States Brace for Obamacare Monday, 1 Apr 2013 | 10:54 AM ET

  

  With only six months before the start of enrollment for Obamacare, state and federal health officials are racing to get insurance regulations and systems up and running in time.

• UPDATE 4-Novartis loses landmark India cancer drug patent case Monday, 1 Apr 2013 | 10:41 AM ET

  MUMBAI/ NEW DELHI, April 1- India's top court dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics.

• India hails "historic" Supreme Court drug patent ruling against Novartis Monday, 1 Apr 2013 | 6:57 AM ET

  NEW DELHI, April 1- The Indian government hailed as "historic" a Supreme Court ruling on Monday against a plea by Swiss drugmaker Novartis AG to protect the patent on its drug Glivec.

• India's Top Court Rejects Novartis Patent Protection Monday, 1 Apr 2013 | 3:56 AM ET

  

  India's top court has dealt a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales.